Insiders who reported open-market trades in the last 12 months at the companies Thomas G. Wiggans files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Thomas G. Wiggans is a corporate insider, tracked as Director of Jasper Therapeutics, Inc. (JSPR). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Thomas G. Wiggans submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Thomas G. Wiggans been buying or selling stock?
Recorded transactions: 2 open-market purchases ($100K) and 0 open-market sales across all tracked filings.
Thomas G. Wiggans is Director of Jasper Therapeutics, Inc. (JSPR). 5 SEC Form 4 filings on record going back to 2025, most recently on 4 August 2026. Most recent open-market trade: bought $100K of JSPR on 24 September 2025. Lifetime open-market purchases: $100K.
Recent transactions
1
The latest SEC Form 4 transaction reported by Thomas G. Wiggans.
InsiderAlpha's records for Thomas G. Wiggans go back to 2025: 5 primary Form 4 filings, an average of 2.5 per year. The typical open-market purchase is $100K (1 of 2 buys carry a usable dollar value, totaling $100K). The largest single buy on record is $100K of JSPR in 2025. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
